News
Aravive (ARAV) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.61 per share a year ago. These figures are ...
Aravive (NASDAQ:ARAV) lost ~62% in the pre-market Thursday after the company said that its lead candidate, batiraxcept, did not reach the main goal in a Phase 3 trial for patients with platinum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback